Feature

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...

May 6, 2025

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

NEWS

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

Radiology Today spotlights Perimeter’s next-gen, AI-enabled B-Series OCT for interoperative cancer margin assessment during breast-conserving surgeries

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Arch advancing game-changing therapies for global kidney care

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

NEWS

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

Ekso Bionics accepted into NVIDIA Connect program

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

Radiology Today spotlights Perimeter’s next-gen, AI-enabled B-Series OCT for interoperative cancer margin assessment during breast-conserving surgeries

Zynex submits FDA application for NiCO device

IPA reports new results validating in silico epitope mapping application

FDA accepts Omeros’ BLA resubmission for narsoplimab in TA-TMA

WHO approves Moleculin’s name for next-gen anthracycline

Just a few of the companies we’ve highlighted along the way

Subscribe